Business
Cronos to enter the Netherlands with acquisition of Europe’s largest adult-use cannabis company
Cronos to acquire CanAdelaar for up-front cash consideration of US$67.0M1 plus cash earnout of 0.5x normalized EBITDA in 2026 and 2027 Up-front consideration represents approximately 1.4x CanAdelaar LTM revenue and 2.4x LTM EBITDA2 Will give Cronos #1 market share3 in the largest adult-use cannabis market in Europe Enables borderless product strategy, leveraging investments in genetics, R&D, and product development TORONTO, Dec. 09, 2025 (GLOBE NEWSWIRE) -- Cronos Group Inc. (NASDAQ: CRON) (TSX:
About this update from Cronos Group Inc
[{"type":"image","alt":"Cronos Group Inc.","displaySize":"","headline":null,"caption":"Cronos Group Inc.","className":"","disableSlideshowImg":false,"size":{"original":{"width":300,"height":102,"url":"https://media.zenfs.com/en/globenewswire.com/75373afe10c05ae5a834e2fcf04ece19"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/YY_WT5V8TV8S.YkjuSH6Gw--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTE0MztjZj13ZWJw/https://media.zenfs.com/en/globenewswire.com/75373afe10c05ae5a834e2fcf04ece19","width":300,"height":102}},"lazy":false},{"type":"text","content":"Cronos to acquire CanAdelaar for up-front cash consideration of US$67.0M1 plus cash earnout of 0.5x normalized EBITDA in 2026 and 2027 ","length":134,"tagName":"p"},{"type":"text","content":"Up-front consideration represents approximately 1.4x CanAdelaar LTM revenue and 2.4x LTM EBITDA2","length":96,"tagName":"p"},{"type":"text","content":"Will give Cronos #1 market share3 in the largest adult-use cannabis market in Europe","length":84,"tagName":"p"},{"type":"text","content":"Enables borderless product strategy, leveraging investments in genetics, R&D, and product development","length":120,"tagName":"p"},{"type":"text","content":"TORONTO, Dec. 09, 2025 (GLOBE NEWSWIRE) -- Cronos Group Inc. (NASDAQ: CRON) (TSX: CRON) (“Cronos” or the “Company”), an innovative global cannabinoid company, is pleased to announce that its wholly-owned subsidiary has entered into a definitive share sale and purchase agreement (the “Purchase Agreement”) to acquire all of the outstanding shares of CanAdelaar B.V. (“CanAdelaar”), the largest cannabis company3 operating within the Netherlands’ adult-use cannabis pilot program (the “Wietexperiment”). Under the Purchase Agreement, the shares of CanAdelaar will be acquired for up-front consideration of €57.5 million, or US$67.0 million,1 subject to certain customary adjustments, with additional contingent consideration payable in cash based on 0.5x of CanAdelaar’s normalized EBITDA in 2026 and 2027 (the “Transaction”).","length":825,"tagName":"p"},{"type":"text","content":"“Our acquisition of CanAdelaar is a financially compelling and highly strategic transaction that will establish a strategic footprint in Europe and enable us to leverage our investments in borderless products,” said Mike Gorenstein, Chairman, President and CEO of Cronos. “The Netherlands has a deep cannab...